Medigen Vaccine Biologics (6547) reported revenue of NT$100 million for Oct 2026, +43.2% year on year and -51.7% from the previous month. Revenue for Jan–Oct 2026 was NT$811.9 million (+51.5% year on year).
Year-on-year revenue growth: 3 months in a row. →
In Oct 2026, it ranked No. 73 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$100 million | +43.2% | -51.7% |
| Sep 2026 | NT$207.2 million | +98.8% | -12.4% |
| Aug 2026 | NT$236.4 million | +416.9% | +399.0% |
| Jul 2026 | NT$47.4 million | -15.3% | +14.0% |
| Jun 2026 | NT$41.6 million | -26.4% | +19.5% |
| May 2026 | NT$34.8 million | -25.0% | -10.2% |
| Apr 2026 | NT$38.7 million | -7.9% | -11.0% |
| Mar 2026 | NT$43.5 million | -4.6% | +72.0% |
| Feb 2026 | NT$25.3 million | -25.2% | -31.8% |
| Jan 2026 | NT$37.1 million | +3.2% | -12.5% |
| Dec 2025 | NT$42.4 million | +14.5% | +21.6% |
| Nov 2025 | NT$34.8 million | -1.8% | -50.1% |
| Oct 2025 | NT$69.8 million | +23.9% | -33.0% |
| Sep 2025 | NT$104.2 million | -14.9% | +127.8% |
| Aug 2025 | NT$45.7 million | -17.6% | -18.2% |
| Jul 2025 | NT$55.9 million | -14.0% | -1.0% |
| Jun 2025 | NT$56.5 million | +12.4% | +21.8% |
| May 2025 | NT$46.4 million | -44.8% | +10.4% |
| Apr 2025 | NT$42 million | +2.5% | -7.9% |
| Mar 2025 | NT$45.6 million | +73.1% | +35.0% |
| Feb 2025 | NT$33.8 million | +140.7% | -6.0% |
| Jan 2025 | NT$36 million | +97.8% | -2.8% |
| Dec 2024 | NT$37 million | +57.3% | +4.3% |
| Nov 2024 | NT$35.5 million | -43.8% | -37.0% |
| Oct 2024 | NT$56.3 million | -33.4% | -54.0% |
Jan–Oct 2026 cumulative: NT$811.9 million (+51.5% YoY)
Other Biotech & Medical companies
Compare with peers: Medigen Vaccine Biologics vs PEC / Medigen Vaccine Biologics vs Lotus Pharm / Medigen Vaccine Biologics vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本期增加海外營收
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16